Sintilimab Combined With Chemotherapy and SBRT in Limited Metastatic Head and Neck Squamous Cell Carcinoma (LM-HNSCC)

NCT05136768 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

50

Enrollment

UNKNOWN

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma
Metastases
Immunotherapy
Stereotactic Body Radiotherapy

Interventions

DRUG: Sintilimab
RADIATION: SBRT
DRUG: Platinum based chemotherapy

Sponsor

Jun-Lin Yi, MD